SHILCA Syndrome: A Comprehensive Disease Characteristics Report

Disease: SHILCA Syndrome (Spondylo-epiphyseal dysplasia, sensorineural Hearing loss, Impaired Intellectual development, and Leber Congenital Amaurosis) MONDO ID: MONDO:0031007 · OMIM: 619260 · Orphanet: 611207 · Category: Mendelian (autosomal recessive) Causal gene: NMNAT1 (1p36.22; HGNC:17877; NCBI Gene 64802)

Summary

SHILCA syndrome is an ultra-rare autosomal recessive multisystem disorder first delineated in 2020, defined by the tetrad of Spondylo-epiphyseal dysplasia, sensorineural Hearing loss, Impaired intellectual development (with brain MRI anomalies), and Leber Congenital Amaurosis (SHILCA). It is caused by biallelic hypomorphic (dosage-reducing) variants in NMNAT1, the gene encoding the nuclear isoform of nicotinamide mononucleotide adenylyltransferase, the enzyme that catalyzes the terminal step of NAD⁺ biosynthesis. The archetypal mutation is an Alu-mediated intragenic partial duplication (c.299+526_968dup) that reduces, but does not abolish, NMNAT1 expression — a critical point, because complete loss of NMNAT1 is embryonic-lethal in mice. The disorder is extraordinarily rare: only approximately four patients from three families* have been reported worldwide (PMID: 32533184, PMID: 33668384).

Mechanistically, reduced NMNAT1 function lowers nuclear NAD⁺, which compromises PARP1-dependent DNA repair and sirtuin (SIRT1)-dependent stress adaptation and redox buffering. In the best-studied tissue — the retina — this converges on the progressive accumulation of the oxidative DNA adduct 8-oxo-dG, triggering apoptotic photoreceptor loss. The same NAD⁺-dependent vulnerability is inferred to extend to other metabolically demanding, long-lived cells: central neurons and oligodendrocytes (explaining intellectual disability, hypomyelinating leukoencephalopathy, and cerebellar hypoplasia), cochlear hair cells (sensorineural deafness), and chondrocytes (skeletal dysplasia). NMNAT1 sits at the center of a broad allelic series that ranges from isolated non-syndromic Leber congenital amaurosis (LCA9) and cone/cone-rod dystrophy at the mild end, through hereditary spastic paraplegia, to the severe syndromic SHILCA phenotype.

There is no approved disease-modifying therapy; management is entirely supportive and multidisciplinary (low-vision/blindness rehabilitation, cochlear implants, developmental/physical/occupational/speech therapy, orthopedic and dental care), coupled with autosomal-recessive genetic counseling (25% sibling recurrence risk). However, AAV-mediated NMNAT1 gene augmentation preserves retinal structure and function in mouse models, and the oxidative-DNA-damage mechanism, NAD⁺-precursor supplementation, and SARM1 inhibition define rational, actively developing therapeutic avenues. A key diagnostic lesson is that SHILCA is a "WES-negative" structural/splice disorder that evades standard whole-exome sequencing and requires RNA-seq plus (ideally long-read) whole-genome sequencing to solve.

1. Disease Information

Overview. SHILCA is a Mendelian, autosomal recessive, congenital multisystem syndrome combining a severe inherited retinal dystrophy (Leber congenital amaurosis) with sensorineural hearing loss, intellectual disability/brain anomalies, and a severe skeletal (spondylo-epiphyseal) dysplasia. It was first described by Bedoni et al. in 2020 in three children from two unrelated Italian families "presenting with a previously unrecognized autosomal recessive disorder that included a severe form of spondylo-epiphyseal dysplasia, sensorineural hearing loss, intellectual disability and Leber congenital amaurosis (SHILCA)" (PMID: 32533184).

Key identifiers (Finding F010).

Synonyms: "SHILCA syndrome"; "SHILCA"; full name "Spondyloepiphyseal dysplasia, sensorineural Hearing loss, Impaired intellectual development, and Leber Congenital Amaurosis."

Source of information. Knowledge of SHILCA is derived entirely from individual patient case reports and functional/model studies — aggregated disease-level resources are minimal, reflecting its ultra-rare Mendelian nature (F010).

2. Etiology

Primary cause (genetic). SHILCA is a monogenic disorder caused by biallelic (recessive) hypomorphic variants in NMNAT1. There is no environmental, infectious, or multifactorial contribution. The original families carried an Alu-mediated partial duplication of NMNAT1: "Short- and long-read whole-genome sequencing highlighted a duplication involving 2 out of the 5 exons of NMNAT1 main isoform (NM_022787.3), leading to the production of aberrant mRNAs" (PMID: 32533184) (F001).

Genetic risk factors. The disease-defining variants are the NMNAT1 alleles themselves. The second reported patient was compound heterozygous for a novel splice variant and the recurrent duplication: "two heterozygous pathogenic variants in nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1)... c.439+5G>T and c.299+526_968dup" (PMID: 33668384) (F006). Because the phenotype requires residual NMNAT1 activity* (complete loss is lethal), the specific combination of hypomorphic alleles is itself the determinant of whether the syndromic (versus isolated ocular) phenotype emerges.

Environmental risk / protective factors. None established for the human disease. In mouse models, light exposure exacerbates photoreceptor degeneration in sensitized genotypes (compound heterozygous Nmnat1^E257K/−), suggesting phototoxic/oxidative stress can act as a gene–environment modifier of the ocular component (PMID: 29674119) (F007). No protective alleles or dietary/lifestyle protective factors are documented. Conceptually, NAD⁺-precursor availability is a candidate modifiable factor given the biochemical defect, but this is unproven in SHILCA.

Gene–environment interactions. The clearest example is the light-dependent exacerbation of retinal degeneration in hypomorphic Nmnat1 mice (F007). The underlying oxidative DNA-damage mechanism (8-oxo-dG accumulation) implies that oxidative load — metabolic and photic — modulates tissue vulnerability (F003).

3. Phenotypes

SHILCA is a severe, congenital, multisystem phenotype. Orphanet classifies it as "a rare primary bone dysplasia" and expands the core tetrad with prominent CNS, neuromuscular, craniofacial, and dental features (F012).

Ocular natural history (F008). The retinal phenotype follows a stereotyped course: "All patients exhibited early-onset, rapidly progressive bilateral retinal degeneration with pronounced central involvement. The condition was characterized by multiple atrophic lesions that coalesced into a large central retinal scar by age 2. The condition stabilized around 4 years of age" (PMID: 39710161). Patients are hyperopic with undetectable ERG and VEP responses; most retain light-perception vision or better with minimal acuity deterioration after age 2.

Quality of life impact. The combination produces deaf-blindness plus intellectual disability and skeletal/motor disability — among the most severe possible multi-domain impairments — with lifelong dependence and need for specialized education and rehabilitation (F015). No disease-specific EQ-5D/SF-36/PROMIS data exist given the tiny patient count.

4. Genetic / Molecular Information

Causal gene. NMNAT1 (nicotinamide mononucleotide adenylyltransferase 1), chromosome 1p36.22, ENSG00000173614, HGNC:17877, OMIM gene 608700, transcript NM_022787. It encodes the nuclear NAD⁺-synthesizing enzyme (F002, F009, F011).

Pathogenic variants in SHILCA. - c.299+526_*968dup — recurrent Alu-mediated intragenic partial duplication (2 of 5 exons), producing aberrant mRNAs; reduces expression ~4-fold (hypomorphic, not null) (PMID: 32533184). - c.439+5G>T — novel non-canonical splice variant producing aberrant transcripts (second patient, compound heterozygous with the duplication) (PMID: 33668384).

All variants are germline, autosomal recessive, with a loss/reduction-of-function (hypomorphic) consequence — not gain of function (F009).

Broader NMNAT1 allelic series (F004). NMNAT1 exhibits a remarkable genotype–phenotype spectrum, with most pathogenic variants clustering in exon 5:

The most common allele, p.Glu257Lys, "was observed in 38 of 106 alleles (35.8%)" and "is considered not fully penetrant" — it "was 80-fold less frequent in a homozygous state in patients... than predicted based on its heterozygosity frequency" (PMID: 24830548) (F004, F009).

Population allele frequencies (gnomAD v4; F009).

This frequency structure — a common weak hypomorph alongside ultra-rare genuinely deleterious alleles — explains why isolated LCA9 is the predominant presentation while syndromic SHILCA is vanishingly rare (F009).

Modifier genes / epigenetics / chromosomal abnormalities. No specific modifier genes are established for SHILCA, though p.E257K has been proposed to act as a modifier allele in other LCA genetic subtypes (PMID: 24940029, supportive). No disease-specific DNA-methylation or histone-modification signature is defined. No large-scale chromosomal abnormality is involved — the lesion is a small intragenic structural (duplication) variant detectable only by WGS (F014).

5. Environmental Information

SHILCA is a purely genetic disorder; no environmental, lifestyle, or infectious etiology applies. The only environmental modifier with experimental support is light exposure, which exacerbates retinal degeneration in sensitized hypomorphic Nmnat1 mouse models (F007, PMID: 29674119). No toxin, radiation, occupational exposure, dietary factor, or infectious agent is implicated.

6. Mechanism / Pathophysiology

Ordered causal chain

1. Biallelic hypomorphic NMNAT1 variants (Alu-mediated partial duplication ± splice variant) → reduced NMNAT1 mRNA/protein (~4-fold downregulation in patient fibroblasts) — demonstrated (PMID: 32533184).
2. Reduced NMNAT1 enzyme → decreased nuclear NAD⁺ biosynthesis (NMNAT1 catalyzes the terminal step, NMN + ATP → NAD⁺) — demonstrated biochemically (F011, F013).
3. Lower nuclear NAD⁺ → impaired PARP1-dependent DNA repair and reduced SIRT1-dependent stress/redox adaptation — inferred from NMNAT1–PARP1 interaction and NAD⁺ biology (F011, F013).
4. Impaired repair + redox buffering → accumulation of oxidative DNA damage (8-oxo-dG) in vulnerable post-mitotic cells — demonstrated in photoreceptors (PMID: 41922335) (F003).
5. Oxidative DNA damage → apoptotic cell loss — demonstrated in photoreceptors; inferred for other tissues (F003).
6. Branch point — tissue-specific manifestations (driven by high metabolic/NAD⁺ demand and cell longevity):
7. → Photoreceptors degenerate → Leber congenital amaurosis (demonstrated).
8. → Central neurons / oligodendrocytes → intellectual disability, hypomyelinating leukoencephalopathy, cerebellar hypoplasia (inferred).
9. → Cochlear hair cells → sensorineural hearing loss (inferred).
10. → Chondrocytes / skeletal tissue → spondylo-epiphyseal dysplasia (inferred).
11. Loss of NMNAT1's NAD⁺-independent chaperone/proteostasis function may additionally compromise neuronal maintenance — inferred from invertebrate/in-vitro data (F002, F013, F016).

Mechanistic detail

Molecular pathway. NAD⁺ biosynthesis (KEGG hsa00760 nicotinamide/nicotinate metabolism; Reactome NAD biosynthesis): NMN/NaMN + ATP → NAD⁺, catalyzed by NMNAT1, feeding PARP1 (DNA repair) and sirtuin/SIRT1 signaling (F011, F013). NMNAT1 "catalyzes the final step in NAD+ biosynthesis and represents the major nuclear isoform of the mammalian NMNAT family," and NAD⁺ "supports redox reactions, DNA repair, chromatin regulation, stress adaptation, inflammation, and neuronal maintenance" (PMID: 42646333) (F013).

Protein dysfunction. NMNAT1 (UniProt Q9HAN9) is a 279-amino-acid nuclear homohexameric enzyme (PDB 1KKU) that forms NAD⁺ from NMN + ATP (and deamido-NAD⁺ from NaMN), physically interacts with PARP1, and localizes to the nucleus (GO:0005634) (F011). Hypomorphic alleles reduce enzyme dosage rather than abolishing activity; NMNAT1 also "acts as a chaperone that protects against neuronal activity-induced degeneration" (PMID: 22842229).

Cellular processes & tissue damage. The demonstrated process is oxidative DNA damage → apoptosis: "reduced NMNAT1 enzyme function due to the p.V9M mutation leads to DNA damage in PRs, characterized by the progressive accumulation of the oxidative DNA adduct 8-oxo-dG" preceding apoptotic photoreceptor loss (PMID: 41922335) (F003). NMNAT1 dysfunction is more broadly linked to "aging-associated genomic instability, neuroinflammation, synaptic impairment, retinal degeneration" (PMID: 42646333) (F013).

Why photoreceptors first? NMNAT1 is ubiquitously expressed, yet reduced function preferentially injures photoreceptors — implicating their exceptionally high metabolic and NAD⁺ demand and light-driven oxidative load (F003).

Ontology suggestions

• GO biological process: NAD biosynthetic process (GO:0009435); nicotinamide-nucleotide adenylyltransferase activity (GO:0000309); DNA repair; apoptotic process.
• GO cellular component: nucleus (GO:0005634).
• CL cell types: retinal photoreceptor cell (CL:0000210); cochlear hair cell (CL:0000202); oligodendrocyte (CL:0000128); chondrocyte (CL:0000138); neuron (CL:0000540).
• CHEBI: NAD⁺ (CHEBI:57540); NMN (CHEBI:16171); ATP (CHEBI:30616); deamido-NAD⁺/NaAD (CHEBI:18304).

7. Anatomical Structures Affected

Organ level. - Primary: eye/retina, inner ear/cochlea, central nervous system (cerebrum, cerebellum, white matter), skeleton (vertebral column, long-bone epiphyses). - Body systems: nervous (CNS + special senses), musculoskeletal, sensory (visual, auditory).

Tissue and cell level (F012).

Subcellular level. The primary compartment is the nucleus (GO:0005634), where NMNAT1 synthesizes NAD⁺ and interacts with PARP1 (F011). Downstream oxidative DNA damage affects nuclear genomic DNA.

Localization / lateralization. Retinal degeneration is bilateral with pronounced central (macular) involvement, coalescing into a central scar (PMID: 39710161) (F008). CNS involvement is diffuse/bilateral (leukoencephalopathy, cerebral/cerebellar hypoplasia); skeletal involvement is generalized/axial (platyspondyly, epiphyseal) (F012).

8. Temporal Development

Onset. Congenital. The retinal phenotype is present at birth (Leber congenital amaurosis), and skeletal, auditory, and neurodevelopmental features manifest in infancy (F008, F012, F015).

Progression (ocular). A distinctive triphasic course: congenital severe deficit → rapid progression with atrophic lesions coalescing into a central scar by age 2 → stabilization around age 4 (PMID: 39710161) (F008). This pattern distinguishes NMNAT1-LCA from many other LCA genotypes.

Progression (systemic). Intellectual disability, hearing loss, and skeletal dysplasia are chronic, lifelong, non-remitting. Hypomyelinating leukoencephalopathy and cerebellar hypoplasia imply ongoing neurological morbidity (F012, F015).

Patterns. No spontaneous or treatment-induced remission. The ocular critical window for intervention is the first years of life, before photoreceptor loss is complete — relevant to the stabilization-by-age-4 natural history and to gene-therapy timing (F008, F005).

9. Inheritance and Population

Epidemiology. Ultra-rare. Approximately four patients from three families have been reported worldwide (three original Italian patients plus one Spanish patient) (F001, F006). No reliable prevalence/incidence figures exist; it is below Orphanet's reporting thresholds. The extreme rarity is explained by the requirement for two ultra-rare deleterious hypomorphic alleles (F009).

Inheritance. Autosomal recessive, with full penetrance for the biallelic genotypes described. Reported genotypes: homozygous partial duplication (consanguineous/shared-haplotype Italian families) and compound heterozygous duplication + splice variant (F001, F006). Recurrence risk for carrier couples is 25% per pregnancy (F015).

Penetrance / expressivity. The syndromic SHILCA genotypes are penetrant. By contrast, the common NMNAT1 allele p.E257K is incompletely penetrant (PMID: 24830548), and the overall allelic series shows wide expressivity (isolated LCA → cone-rod dystrophy → HSP → syndromic SHILCA), governed by residual enzyme activity (F004).

Founder effects / consanguinity. The original Italian families shared an identical haplotype across a 4.76 Mb autozygous region, consistent with a shared ancestral allele / consanguinity-related homozygosity (F001). No broad founder population is defined.

Carrier frequency. For deleterious SHILCA alleles, carrier frequency is essentially unmeasurable (private variants not in gnomAD). The common hypomorph p.E257K has a carrier frequency of ~1/485, but this allele alone does not cause SHILCA (F009).

Demographics. Reported patients are of European (Italian, Spanish) ancestry; no sex bias is evident (autosomal). Age at report was very young (~2 years) (F006, F015).

10. Diagnostics

Key diagnostic lesson (F014). SHILCA is a WES-negative structural/splice disorder. In the index families, "whole-exome sequencing failed to identify any shared rare coding variants, in this region or elsewhere"; the diagnosis was reached only because "we then determined the transcriptome of patients' fibroblasts by RNA sequencing, followed by additional whole-genome sequencing experiments" (PMID: 32533184).

Recommended diagnostic pathway. 1. Clinical gestalt — recognize the LCA + sensorineural hearing loss + skeletal dysplasia + intellectual disability combination. 2. Ophthalmic workup — ERG/VEP (undetectable), OCT (outer-retinal disruption, RPE atrophy), fundus autofluorescence, fluorescein angiography (central hypofluorescence with visible choroidal vasculature) (PMID: 39710161) (F008). 3. Brain MRI — hypomyelination/leukoencephalopathy, cerebellar hypoplasia (F012). 4. Skeletal survey — spondylo-epiphyseal dysplasia, platyspondyly (F012). 5. Molecular testing — NMNAT1 sequencing / IRD gene panel first; if negative despite strong phenotype, escalate to WGS (short + long read) and/or fibroblast RNA-seq to detect structural/splice variants (F014).

Biomarkers. No validated circulating biomarker; research assays include reduced NMNAT1 transcript/protein and increased 8-oxo-dG (mechanistic, not clinical) (F003, F014).

Clinical criteria / differential diagnosis. No formal criteria exist. Differentials include other syndromic LCAs and other causes of deaf-blindness with skeletal dysplasia; the distinctive NMNAT1-LCA retinal natural history (central scar by age 2, stabilizing by age 4) plus the specific multisystem combination point to SHILCA.

NCIT terms: Whole Genome Sequencing (C101294); RNA Sequencing (C101295); Whole Exome Sequencing (C101293).

11. Outcome / Prognosis

Overall (F015). SHILCA is a congenital, chronic, non-remitting disorder producing lifelong severe multi-domain disability: profound early blindness, permanent sensorineural deafness, intellectual disability, and skeletal dysplasia (i.e., deaf-blindness plus ID plus motor/skeletal impairment).

Visual prognosis. Profound from birth; "most patients maintained light perception vision or better, with minimal deterioration of visual acuity after the age of 2" (PMID: 39710161) (F015). No meaningful spontaneous visual recovery.

Survival/mortality. Not quantifiable given ~4 reported patients; youngest described at ~age 2, no disease-specific mortality figure. Severe hypomyelinating leukoencephalopathy, hypotonia, and ataxia imply substantial morbidity (F015).

Morbidity / function. Combined sensory (vision + hearing), cognitive, and motor/skeletal disability; high lifelong care dependency.

Prognostic factors. Residual NMNAT1 activity (genotype severity) is the principal determinant of where a patient falls on the allelic spectrum (F004).

12. Treatment

Current standard — supportive only (F015). There is no approved disease-modifying therapy, and "no human trial has yet established efficacy for an NMNAT-1-directed neurological therapy" (PMID: 42646333) (F013). Management is multidisciplinary: - Sensorineural hearing loss: cochlear implants/hearing aids; auditory-verbal therapy (NCIT: Cochlear Implant C16623). - Vision: low-vision/blindness rehabilitation, special education. - Neurodevelopment / hypotonia / ataxia: developmental, physical, occupational, and speech therapy (NCIT: Physical Therapy C15415). - Skeletal dysplasia: orthopedic surveillance and management of spinal/joint disease. - Dental care for irregular dentition. - Genetic counseling (NCIT: Genetic Counseling C15671; Supportive Care C15346).

Advanced / experimental therapeutics (preclinical; F005). - AAV gene augmentation: "Gene Therapy Preserves Retinal Structure and Function in a Mouse Model" of NMNAT1-associated disease, where "no treatment is available" (PMID: 32775493). Photoreceptor-targeted expression is sufficient: "Expression of NMNAT1 in the photoreceptors is sufficient to prevent" degeneration (PMID: 37214313) — defining a photoreceptor-autonomous target. - Antioxidant / DNA-damage-targeted approaches: the 8-oxo-dG oxidative-DNA-damage mechanism was explicitly flagged as "a therapeutic opportunity" (PMID: 41922335). - NAD-pathway strategies: "Current therapeutic approaches include SARM1 inhibitors in clinical trials, gene therapy, and NAD precursor supplementation" (PMID: 42341897) (F005).

Pharmacogenomics. Not applicable (no disease-specific pharmacotherapy).

13. Prevention

Because SHILCA is purely genetic and congenital, primary prevention is not possible by lifestyle/environmental means (F015).

• Genetic counseling (primary preventive tool): autosomal recessive counseling with 25% sibling recurrence risk; cascade carrier testing once both familial NMNAT1 alleles are identified.
• Reproductive options: prenatal diagnosis and preimplantation genetic testing for monogenic disease (PGT-M) are available to known carrier couples (F015).
• Secondary prevention: early ophthalmic, audiologic, neurodevelopmental, and skeletal surveillance to optimize supportive intervention (cochlear implantation, low-vision rehabilitation, early developmental therapy) within critical developmental windows.
• Tertiary prevention: orthopedic monitoring to prevent/limit complications of spondylo-epiphyseal dysplasia; management of leukoencephalopathy-related morbidity.
• Immunization / public-health / environmental interventions: not applicable.

NCIT: Genetic Counseling (C15671).

14. Other Species / Natural Disease

Taxonomy and orthologs (F016). NMNAT1 is deeply conserved:

The NMNAT enzyme family is conserved to yeast (F016).

Natural disease. No naturally occurring animal equivalent of SHILCA is cataloged in OMIA — all animal disease models are engineered (F016). No companion-animal or wildlife natural counterpart, and no zoonotic/cross-species transmission applies.

Comparative biology / conserved neuroprotection. NMNAT's neuroprotective role is evolutionarily conserved. In Drosophila, "in vivo neuronal expression of mutated nmnat shows that enzymatically inactive NMNAT protein retains strong neuroprotective effects and rescues the degeneration phenotype caused by loss of nmnat" (PMID: 17132048) — evidence for an NAD⁺-independent chaperone function. In mammals, the WldS fusion (Ube4b–Nmnat1) delays axon degeneration, and "increased Nmnat activity is responsible for the axon-sparing activity of the Wlds protein," with increased nuclear NAD biosynthesis and SIRT1 activation preventing axonal degeneration (PMID: 15310905) (F016).

15. Model Organisms

Mouse models (primary; F007).

Invertebrate models. Drosophila Nmnat mutants cause rapid activity-dependent neurodegeneration; enzymatically inactive NMNAT still rescues, demonstrating a chaperone function (PMID: 17132048) (F016).

Model characteristics & limitations. Mouse models recapitulate the retinal (ocular) component of SHILCA well and have validated both mechanism (oxidative DNA damage) and therapy (gene augmentation). However, no published model recapitulates the full multisystem SHILCA phenotype (skeletal dysplasia + hearing loss + leukoencephalopathy together); modeling to date has focused on the retina (F007, F016). Dosage is critical — null alleles are lethal, so SHILCA modeling requires hypomorphic/conditional strategies.

Resources: MGI (mouse Nmnat1, Gene 66454); FlyBase (Nmnat); ZFIN (nmnat1).

Mechanistic Model (Synthesis)

 Biallelic hypomorphic NMNAT1 variants
 (Alu-mediated partial duplication ± splice variant; germline, AR)
            │  demonstrated (RNA-seq ~4x downregulation; WGS)
            ▼
 Reduced NMNAT1 enzyme dosage  ──(residual activity preserved;
            │                      complete loss = embryonic lethal)
            ▼
 Decreased NUCLEAR NAD+ biosynthesis (NMN + ATP → NAD+)
            │  demonstrated biochemically
            ▼
 Impaired PARP1 DNA repair  +  reduced SIRT1 redox/stress adaptation   [inferred]
            ▼
 Accumulation of oxidative DNA damage (8-oxo-dG)   [demonstrated in photoreceptors]
            ▼
 Apoptosis of metabolically demanding, long-lived cells
   ├── Photoreceptors ........ Leber congenital amaurosis   [demonstrated]
   ├── Neurons/oligodendrocytes .. ID, leukoencephalopathy, cerebellar hypoplasia [inferred]
   ├── Cochlear hair cells ... sensorineural hearing loss   [inferred]
   └── Chondrocytes .......... spondylo-epiphyseal dysplasia [inferred]

The retinal arm of this chain is experimentally established end-to-end; the extra-ocular arms are mechanistically plausible extrapolations of the same NAD⁺-deficiency logic applied to cells with high metabolic demand and limited renewal.

Evidence Base

Evidence-type caveat. Several SHILCA/NMNAT1 citation snippets were flagged [mismatch] during validation (e.g., the exact variant-nomenclature quotes from 33668384 and the NMNAT1-review quotes from 42646333). The underlying claims are consistent with the papers' reported findings, but the verbatim snippets should be re-verified against the published abstracts before being entered as exact quotes in a knowledge base.

Limitations and Knowledge Gaps

1. Extreme rarity (n ≈ 4). All clinical knowledge derives from ~4 patients in 3 families. Penetrance, expressivity, full phenotypic range, prognosis, survival, and natural history of the extra-ocular features are essentially uncharacterized.
2. Extra-ocular mechanism is inferred, not demonstrated. The oxidative-DNA-damage → apoptosis chain is proven only in photoreceptors. Its application to chondrocytes, cochlear hair cells, and oligodendrocytes is a reasonable but untested extrapolation.
3. No multisystem model. All animal models capture the retinal phenotype; none recapitulates the skeletal, auditory, and leukoencephalopathy triad simultaneously.
4. No validated clinical biomarker or formal diagnostic criteria; diagnosis relies on expert gestalt plus escalated genomic testing.
5. No human therapeutic evidence. Gene therapy and NAD-pathway strategies are preclinical/retina-focused; none addresses the systemic disease.
6. Genotype–phenotype rules are incomplete. Why specific hypomorphic combinations yield syndromic SHILCA versus isolated LCA9 is not quantitatively defined (residual-activity thresholds are hypothesized, not measured per allele).
7. Citation-snippet mismatches (above) require manual verification.

Proposed Follow-up Experiments / Actions

1. International patient registry / GeneMatcher outreach — aggregate additional SHILCA cases to define phenotype frequencies, natural history of extra-ocular features, and prognosis.
2. Allele-resolved enzymatic assays — quantify residual NMNAT1 activity/NAD⁺ output for each hypomorphic allele (duplication, splice, E257K, V9M) to test the residual-activity-threshold model of genotype–phenotype correlation.
3. Multisystem mouse model — generate hypomorphic/compound-heterozygous Nmnat1 alleles matching patient genotypes (e.g., humanized duplication) and phenotype the skeleton, cochlea, and brain, not just the retina.
4. Mechanistic validation in extra-ocular cell types — measure nuclear NAD⁺, PARP1 activity, and 8-oxo-dG in patient-derived iPSC-chondrocytes, otic organoids, and oligodendrocytes to test whether the retinal mechanism generalizes.
5. Therapeutic testing of NAD⁺ precursors ± SARM1 inhibition — assess whether systemic NAD⁺ boosting (NR/NMN) or SARM1 inhibition mitigates extra-ocular degeneration in a multisystem model; the retina-focused AAV strategy cannot reach skeleton/CNS equally.
6. Diagnostic protocol dissemination — publish/endorse a tiered algorithm (IRD panel → WGS short+long read → fibroblast RNA-seq) so that WES-negative SHILCA cases are reliably solved.
7. Verify flagged citation snippets against source abstracts (33668384 37214313 42646333) before knowledge-base entry.

Prepared from 16 confirmed findings across 5 investigation iterations and 39 reviewed papers. Evidence spans human clinical case reports, mouse/Drosophila model organism studies, in-vitro biochemistry, and computational/population-genetic data.